IL-4 suppresses very late antigen-4 expression which is required for therapeutic th1 t-cell trafficking into tumors

Journal of Immunotherapy

Volumn 32, Issue 8, 2009, Pages 793-802

  Sasaki, Kotaro ^a   Pardee, Angela D ^a   Qu, Yanyan ^a   Zhao, Xi ^a   Ueda, Ryo ^a   Kohanbash, Gary ^a   Bailey, Lisa M ^a   Okada, Hideho ^a,b   Muthuswamy, Ravikumar ^a   Kalinski, Pawel ^a   Basse, Per H ^a,b   Falo, Louis D ^a,b   Storkus, Walter J ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

IL 4; Melanoma; T helper 1; VLA 4; VLA 6

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12P70; INTERLEUKIN 4 RECEPTOR; LAMININ; RECOMBINANT INTERLEUKIN 4; STAT6 PROTEIN; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 4; VERY LATE ACTIVATION ANTIGEN 6;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ADHESION; CELL CULTURE; CELL HOMING; CELL POPULATION; CELL THERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; LYMPHOCYTE MIGRATION; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TH1 CELL; TH2 CELL; TUMOR MODEL;

ANIMALS; ANTIBODIES, BLOCKING; ANTIGENS, CD8; CELL MOVEMENT; IMMUNOTHERAPY, ADOPTIVE; INTEGRIN ALPHA4BETA1; INTEGRIN ALPHA6BETA1; INTERLEUKIN-4; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; TH1 CELLS; TH2 CELLS;

EID: 70349694504     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181acec1e     Document Type: Article

References (37)

1. Mosmann TR, Co.man RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol. 1989;7:145-173.
2. O'Garra A. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity. 1998;8: 275-283.
3. Weaver CT, Hatton RD, Mangan PR, et al. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol. 2007;25:821-852.
4. Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17- producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6: 1123-1132.
5. Sakaguchi S, Sakaguchi N, Shimizu J, et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev. 2001; 182:18-32.
6. Chen Y, Kuchroo VK, Inobe J, et al. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science. 1994;265:1237-1240.
7. Lichtman AH, Abbas AK. T-cell subsets: recruiting the right kind of help. Curr Biol. 1997;7:R242-R244.
8. O'Garra A, McEvoy LM, Zlotnik A. T-cell subsets: chemokine receptors guide the way. Curr Biol. 1998;8:R646-R649.
9. Syrbe U, Siveke J, Hamann A. Th1/Th2 subsets: distinct di.erences in homing and chemokine receptor expression? Springer Semin Immunopathol. 1999;21:263-285.
10. Austrup F, Vestweber D, Borges E, et al. P- and E-selectin mediate recruitment of T-helper-1 but not T-helper-2 cells into in.ammed tissues. Nature. 1997;385:81-83.
11. Bonecchi R, Bianchi G, Bordignon PP, et al. Differential expression of chemokine receptors and chemotactic responsiveness responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med. 1998;187:129-134.
12. Sasaki K, Zhu X, Vasquez C, et al. Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in tra.cking into central nervous system tumors. Cancer Res. 2007;67:6451-6458.
13. Nishimura F, Dusak JE, Eguchi J, et al. Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10. Cancer Res. 2006;66:4478-4487.
14. Jarnicki AG, Lysaght J, Todryk S, et al. Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells in.ltrating the growing tumor: in.uence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol. 2006;177:896-904.
15. Bix M, Wang ZE, Thiel B, et al. Genetic regulation of commitment to interleukin 4 production by a CD4+ T cellintrinsic mechanism. J Exp Med. 1998;188:2289-2299.
16. Nelms K, Keegan AD, Zamorano J, et al. The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol. 1999;17:701-738.
17. Kaplan MH, Schindler U, Smiley ST, et al. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity. 1996;4:313-319.
18. Lobb RR, Hemler ME. The pathophysiologic role of alpha 4 integrins in vivo. J Clin Invest. 1994;94:1722-1728.
19. Shimizu Y, Van Seventer GA, Horgan KJ, et al. Regulated expression and binding of three VLA (beta 1) integrin receptors on T cells. Nature. 1990;345:250-253.
20. Shimizu Y, van Seventer GA, Horgan KJ, et al. Roles of adhesion molecules in T-cell recognition: fundamental similarities between four integrins on resting human T cells (LFA-1, VLA-4, VLA-5, VLA-6) in expression, binding, and costimulation. Immunol Rev. 1990;114:109-143.
21. Marzo AL, Kinnear BF, Lake RA, et al. Tumor-specific CD4+ T cells have a major ''post-licensing'' role in CTL mediated antitumor immunity. J Immunol. 2000;165:6047-6055.
22. Wong SB, Bos R, Sherman LA. Tumor-specific CD4+ T cells render the tumor environment permissive for in.ltration by low-avidity CD8+ T cells. J Immunol. 2008;180: 3122-3131.
23. Wang LX, Shu S, Disis ML, et al. Adoptive transfer of tumorprimed, in vitro-activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response. Blood. 2007;109: 4865-4876.
24. Hu HM, Winter H, Urba WJ, et al. Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy. J Immunol. 2000;165:4246-4253.
25. Whiteside TL. Signaling defects in T lymphocytes of patients with malignancy. Cancer Immunol Immunother. 1999;48: 346-352.
26. Kageshita T, Hirai S, Ono T, et al. Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am J Pathol. 1999;154: 745-754.
27. Fearon ER, Pardoll DM, Itaya T, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell. 1990;60: 397-403.
28. Antony PA, Piccirillo CA, Akpinarli A, et al. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol. 2005;174:2591-2601.
29. Shrikant P, Khoruts A, Mescher MF. CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism. Immunity. 1999;11: 483-493.
30. Schoenberger SP, Toes RE, van der Voort EI, et al. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 1998;393:480-483.
31. Ribas A, Butter.eld LH, Amarnani SN, et al. CD40 crosslinking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modi.ed dendritic cells. Cancer Res. 2001;61:8787-8793.
32. Lode HN, Xiang R, Pertl U, et al. Melanoma immunotherapy by targeted IL-2 depends on CD4(+) T-cell help mediated by CD40/CD40L interaction. J Clin Invest. 2000;105: 1623-1630.
33. Ogawa M, Umehara K, Yu WG, et al. A critical role for a peritumoral stromal reaction in the induction of T-cell migration responsible for interleukin-12-induced tumor regression. Cancer Res. 1999;59:1531-1538.
34. Zheng W, Flavell RA. The transcription factor GATA-3 is necessary and su.cient for Th2 cytokine gene expression in CD4 T cells. Cell. 1997;89:587-596.
35. Ho IC, Lo D, Glimcher LH. c-maf promotes T helper cell type 2 (Th2) and attenuates Th1 differentiation by both interleukin 4-dependent and -independent mechanisms. J Exp Med. 1998;188:1859-1866.
36. Marinkovich MP. Tumour microenvironment: laminin 332 in squamous-cell carcinoma. Nat Rev Cancer. 2007;7:370-380.
37. Miyazaki K. Laminin-5 (laminin-332): unique biological activity and role in tumor growth and invasion. Cancer Sci. 2006;97:91-98.